Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.
Jean Philippe ColletEric Van BelleHolger ThieleSergio BertiThibault LhermusierThibault ManigoldFranz-Josef NeumannMartine GilardDavid AttiasFarzin BeyguiAngel CequierFernando AlfonsoPierre AubryFlore BaronnetStéphane EderhyMohamad El KastyMathieu KerneisOlivier BarthelemyThierry LefèvrePascal LeprinceAlban RedheuilPatrick HenryJean Jacques PortalEric VicautGilles Montalescotnull nullPublished in: European heart journal (2022)
After TAVI, apixaban was not superior to the standard of care, irrespective of an indication for oral anticoagulation.
Keyphrases
- transcatheter aortic valve implantation
- atrial fibrillation
- venous thromboembolism
- aortic valve
- aortic valve replacement
- aortic stenosis
- healthcare
- palliative care
- quality improvement
- transcatheter aortic valve replacement
- clinical trial
- pain management
- affordable care act
- ejection fraction
- phase iii
- coronary artery disease
- left ventricular
- health insurance